Anlon Healthcare Limited has informed the stock exchanges that its Chairman & Managing Director, Mr. Punitkumar Rasadia, has been invited for a television interview on NDTV Profit. The interview is scheduled to be telecast live on June 11, 2026, at 01:30 P.M. IST under the program "The Small Cap Buzzers". The disclosure was submitted to BSE Limited and The National Stock Exchange of India Ltd. on June 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Discussion Topics

The interaction will focus on the company's growth journey, recent business developments, and financial performance for FY 2025-26. The discussion will also cover the future outlook of the company. The company confirmed that the discussion would be based solely on publicly available information and no unpublished price-sensitive information (UPSI) would be shared during the interview.

Key Details of the Interaction

Anlon Healthcare noted that the interview could be cancelled, rescheduled, or postponed depending on circumstances. The company has requested the exchanges to take the information on record.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0Y8W01025/4a8aaf29e41244a3.pdf

Anlon Healthcare Limited reported a 42.98% year-on-year increase in consolidated total income to ₹172.22 crore for FY26, driven by expanding demand across its pharmaceutical intermediate and API portfolio. Profit after tax grew 41.77% to ₹29.09 crore, while EBITDA increased 47.55% to ₹47.77 crore. The company attributed this performance to improving operational efficiencies and disciplined execution across key business verticals. Management stated it remains confident of delivering approximately 30% revenue CAGR over the next three years while maintaining EBITDA margins in the range of 25 to 30%.

For the fourth quarter ended March 31, 2026, total income stood at ₹50.90 crore compared to ₹48.97 crore in Q4 FY25. Profit before tax for the quarter was broadly stable at ₹14.44 crore versus ₹15.49 crore, while reported PAT of ₹11.07 crore was lower than the ₹16.65 crore in the corresponding quarter. The decline was primarily due to higher operating and development expenses as the company scales its platform.

Financial Performance

Strategic Developments

The company completed the acquisition of Apiqo Organics Private Limited and Bizotic Life Science during the year, strengthening backward integration and adding substantial capacity. With these initiatives, the combined installed capacity has expanded to approximately 1400 to 1600 metric ton per annum. Anlon Healthcare is also developing three molecules for two global innovators to reinforce its long-term strategy to build a scalable custom manufacturing platform.

Future Guidance

Management guided for revenue between ₹380 to 400 crore for FY27, with visibility of an order book around ₹280 to 300 crore. The company expects to be cash flow positive on an annual basis by the end of FY27. A new capex of approximately ₹130 crore is planned for expansion at the existing premises, with construction expected to start by the end of June 2026 and commercial production targeted by Q1 FY28. Funding for the capex will be sourced through a term loan of ₹65 to 70 crore and internal accruals.